Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
SCYX
SCYX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest SCYX ETF News Today | Earnings, Events & Price Alerts
SCYX News
SCYNEXIS Secures FDA QIDP Designation for SCY-247, Ensuring 10 Years of Market Exclusivity
Jan 21 2026
Yahoo Finance
Scynexis Reveals Federal Support for Partnership Between Hackensack Meridian CDI and Johns Hopkins Researchers to Create Innovative Therapies, Including New Fungerps, for Resistant Fungal Infections
Nov 17 2025
Newsfilter
SCYNEXIS Announces Financial Results for Q3 2025 and Shares Corporate Update
Nov 05 2025
Newsfilter
Guggenheim Reiterates Buy Rating on SCYNEXIS, Adjusts Price Target to $3
Oct 28 2025
Benzinga
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Oct 23 2025
NASDAQ.COM
SCYNEXIS Announces Encouraging Phase 1 Findings for Antifungal Candidate SCY-247
Sep 30 2025
NASDAQ.COM
SCYNEXIS to Attend the H.C. Wainwright 27th Annual Global Conference from September 8 to 10, 2025
Aug 25 2025
Newsfilter
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 15 2025
Newsfilter
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Apr 08 2025
Newsfilter
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
Mar 12 2025
Newsfilter
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
Dec 18 2024
Newsfilter
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 06 2024
Newsfilter
SCYNEXIS To Receive $10 Mln Milestone Payment From GSK For Completed Clinical Study Report
Jul 23 2024
NASDAQ.COM
SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024
May 09 2024
Business Insider
SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023
Mar 29 2024
Business Insider
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
Jan 30 2024
businesswire
Show More News
